New 52 Week Low Today

Lyell Immunopharma Inc LYEL:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 4:00 PM EDT
14.41quote price arrow down-0.14 (-0.96%)
Volume
250,763
52 week range
14.00 - 18.90

...

Loading . . .
  • Open14.66
  • Day High14.98
  • Day Low14.00
  • Prev Close14.55
  • 52 Week High18.90
  • 52 Week High Date06/17/21
  • 52 Week Low14.00
  • 52 Week Low Date07/27/21

Key Stats

  • Market Cap3.499B
  • Shares Out242.83M
  • 10 Day Average Volume0.36M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

KEY STATS

  • Open14.66
  • Day High14.98
  • Day Low14.00
  • Prev Close14.55
  • 52 Week High18.90
  • 52 Week High Date06/17/21
  • 52 Week Low14.00
  • 52 Week Low Date07/27/21
  • Market Cap3.499B
  • Shares Out242.83M
  • 10 Day Average Volume0.36M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-0.95
  • P/E (TTM)-15.20
  • Fwd P/E (NTM)-12.11
  • EBITDA (MRQ)-228.827M
  • ROE (MRQ)-
  • Revenue (MRQ)8.95M
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-2,574.34%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Lyell Immunopharma Inc

There is no recent news for this security.

Profile

MORE
Lyell Immunopharma, Inc is a T cell reprogramming company. The Company offers T cells to cure patients with solid tumors. Its technologies are designed to be applied in a target and agnostic manner to chimeric antigen receptor (CAR), tumor-infiltrating lymphocytes (TIL) and T cell receptor (TCR) therapies to improve the properties of T cells to eradicate solid tumors. It builds a multi-modality product pipeline across solid tumor indications with unmet needs and anticipate...
Richard Klausner M.D.
Chairman
Liz Homans
Chief Executive Officer
Stephen Hill
Chief Operating Officer
Charles Newton
Chief Financial Officer
Richard Goold Ph.D.
Chief Information Officer
Address
400 East Jamie Court, Suite 301
South San Francisco, CA
94080
United States